Dr Aiman Shalabi | Chief Medical Officer
Cancer Research Institute

Dr Aiman Shalabi, Chief Medical Officer, Cancer Research Institute

Aiman Shalabi is a global executive with over 20 years’ experience in driving new treatments for patients with cancer.  Aiman’s key strength is aligning multiple stakeholders in areas of complex science to develop a common vision and execute against that vision. He is currently the Chief Medical Officer at the Cancer Research Institute (CRI) where he provides strategic direction and integrated oversight for CRI’s cancer immunotherapy clinical trial program.  Previously, Aiman was the Vice President, Global Medical Affairs group for Immune Oncology at AstraZeneca and was also the Global Product Vice President at AstraZeneca leading the cross-functional development team for PD-L1.  He also led multiple Immuno-oncology programs at MedImmune including an accelerated PD-L1 program from first-in-human to phase III start in 14 months, supported the in-licensing an initiated development of Tremelimumab and OX40 and importantly – initiated the IO combinations studies early in the development cycle.  He also served as the chair of the Joint Steering Committee and implemented novel external collaborations with the Cancer Research Institute, Friends of Cancer Research, SWOG, NCIC (Canada) and the National Cancer Institute (US).  
The majority of Aiman’s experience has been in global drug development (phase III transitions, regulatory applications, product launch, life-cycle management, alliance management).   During his 17 year career in the pharmaceutical industry, he has made meaningful contributions to five global medicines programs that delivered innovative treatments to cancer patients including Durvalumab (anti-PDL1), Tremelimumab (anti-CTLA4), OX40,  Taxotere (docetaxel), Iressa (gefitinib), and Caprelsa (vandetinib).  He has also gained experience across the entire development cycle including CD nominations, IND submissions, first in human studies, NDA/BLA submissions, lifecycle management and product in-licensing in various leadership roles.  
Aiman entered the pharmaceutical industry after a successful career at the National Cancer Institute (CTEP, NCI) where he managed a portfolio of 26 agents and was a member of the review committee for research proposals from the NCI designated cancer centers and US cooperative groups.  He also led the National Cancer Institute Compassionate Use program.  During his time at the NIH, he received a national award for developing programs to provide patients with access to breakthrough medicines for leukemia (Gleevec) and breast cancer (Herceptin) prior to FDA approval.  Aiman also worked in clinical oncology practice with direct patient care responsibilities.    
Aiman has five university degrees including biology, chemistry, pharmaceutical sciences, Doctor of Pharmacy and recently completed an MBA at the Johns Hopkins University.  He obtained Board Certification in Oncology Pharmacy (BCOP) in 1998. 


DC Co-conference Day 2 April 4 @ 12:10

A comprehensive analysis of combination studies in immuno-oncology

  • Summary of all IO agents, targets and companies
  • Overview of ongoing PD-1 combination studies
  • Trends and areas to enhance efficiencies
  • Role of Philanthropy in IO

back to speakers